<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>26 Lymphoma II: Non-Hodgkin lymphoma</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-25-lymphoma-I-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 65%;"></div>
                        </div>
                       <span class="progress-text">Lecture 26 of 40</span>
                    </div>
                    <a href="haematology-27-myeloproliferative-disorders.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">26 Lymphoma II: Non-Hodgkin lymphoma</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="nhl-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>The non-Hodgkin lymphomas (NHLs) are a diverse group of disorders, which encompass a range of clinical presentations, histological appearances and prognostic categories.</p>
                    </div>
                </section>

                <section id="aetiology-epidemiology" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Aetiology and epidemiology</span>
                    </h2>
                    <div class="content-card">
                        <p>Non-Hodgkin lymphoma occurs at all ages, with indolent tumours being most common in the elderly. There is clonal expansion from a normal cell which is 'frozen' at a particular level of differentiation. Most NHLs are B-cell disorders. Environmental factors include abnormal response to viral infection, e.g. Epstein-Barr virus (EBV) in Burkitt's lymphoma (BL) and human T-cell leukaemia virus (HTLV-1) in adult T-cell leukaemia lymphoma (ATLL), or to bacterial infection (e.g. chronic Helicobactor pylori infection in gastric lymphoma), or to radiation or certain drugs (e.g. phenytoin). Autoimmune disease (e.g. Sjögren's syndrome, rheumatoid arthritis) and immune suppression (e.g. AIDS, post-transplant) also predispose to NHL. Chromosome translocations in NHL involving oncogenes and immunoglobulin genes include t(14;18) (follicular lymphoma, BCL 2 oncogene) and t(8;14) (BL, MYC oncogene).</p>
                    </div>
                </section>

                <section id="histological-classification" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Histological classification</span>
                    </h2>
                    <div class="content-card">
                        <p>At least six different classifications for NHL have existed but NHL is now classified as disease entities based on clinical, biological and histological criteria in the REAL system (see p. 72). Membrane marker and molecular studies of NHL show most (&gt;80%) to be derived from B cells (either follicle centre or from other zones in the lymph node), and the remainder are T cell or unclassified. Indolent NHL may evolve into aggressive disease (Figs 26.1-26.4).</p>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-069-1.jpg" alt="Fig. 26.1 Lymph node biopsy of low-grade (indolent) NHL, showing a follicular (nodular) structure." class="content-image">
                            <figcaption>Fig. 26.1 Low-grade (indolent) NHL: lymph node biopsy showing follicular (nodular) structure.</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-069-2.jpg" alt="Fig. 26.2 Lymph node biopsy of high-grade (diffuse) NHL, showing diffuse replacement of the node with large cells and destruction of normal architecture." class="content-image">
                            <figcaption>Fig. 26.2 High grade (diffuse) NHL: lymph node biopsy showing diffuse replacement of the node with large cells and destruction of normal nodal architecture.</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-070-1.jpg" alt="Fig. 26.3 Immunostaining of low-grade NHL showing positive (brown) staining for bcl-2 protein, which inhibits apoptosis." class="content-image">
                            <figcaption>Fig. 26.3 Low-grade NHL: immunostaining showing presence of bcl-2 protein (brown), which prevents apoptosis.</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-070-2.jpg" alt="Fig. 26.4 Immunostaining of high-grade NHL showing positive staining for Ki-67, indicating a high proliferation rate." class="content-image">
                            <figcaption>Fig.26.4 High-grade NHL: immunostaining showing positive staining for Ki 67, indicating high proliferation rate.</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">General</h3>
                        <ul>
                            <li>Similar to Hodgkin lymphoma (HL), including painless lymphadenopathy, hepatic and splenic enlargement, systemic symptoms and infection.</li>
                            <li>Extranodal disease is more common in NHL than in HL. Thus, gastrointestinal, central nervous system, skin, endocrine organ (including testes), pulmonary and ocular lymphomas will all have the characteristic presenting features of tumours affecting these organs.</li>
                        </ul>
                        <h3 class="subsection-heading">Clinical features of sub types of non-Hodgkin lymphoma</h3>
                        <p>Non-Hodgkin lymphoma is clinically heterogeneous, but various clinical patterns emerge.</p>
                        <ul>
                            <li><strong>Chronic lymphocytic leukaemia (CLL)-like:</strong> indolent NHL (small lymphocytic lymphoma (SLL), follicular lymphoma) is more common in older patients (&gt;60 years), is widely disseminated at presentation and may only warrant observation, not treatment. Variants include some T-cell NHL (T-NHL) (e.g. mycosis fungoides) which affect the skin and splenic marginal zone lymphoma predominantly causing splenomegaly.</li>
                            <li><strong>Myeloma-like:</strong> bony disease is uncommon but a paraprotein, lymphadenopathy and splenomegaly may occur with lymphoplasmacytoid lymphomas and Waldenström's macroglobulinaemia (see p. 67).</li>
                            <li><strong>Gastrointestinal lymphomas</strong> include mucosa-associated lymphoid tissue (MALT) lymphoma, and T-cell NHL complicating coeliac disease.</li>
                            <li><strong>Epidemiology-defined aggressive NHL</strong> includes BL (African children, higher incidence in males than females, jaw tumours, EBV related); ATLL (Caribbean and Japan, hypercalcaemia, skin and lymphoid area involvement; HTLV-1 related) and AIDS-related NHL (usually aggressive and frequent central nervous system disease).</li>
                        </ul>
                    </div>
                </section>

                <section id="laboratory-features" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Laboratory features</span>
                    </h2>
                    <div class="content-card">
                        <p>In addition to the changes seen in HL, NHL may cause:</p>
                        <ul>
                            <li>pancytopenia as a result of bone marrow involvement leading to bone marrow failure;</li>
                            <li>peripheral blood lymphocytosis caused by the presence of lymphoma cells in the blood; and</li>
                            <li>paraprotein and hypogammaglobulinaemia.</li>
                        </ul>
                    </div>
                </section>

                <section id="staging" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Staging</span>
                    </h2>
                    <div class="content-card">
                        <p>This is of less importance than in HL. More than 50% of patients with indolent NHL have stage IV disease, whereas aggressive NHL is often of early stage.</p>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>This depends principally on histology. Paradoxically, aggressive tumours respond more dramatically to treatment and are more likely to be cured than indolent tumours; however, they are also more aggressive if untreated, frequently relapse and are associated with higher short- to medium-term mortality.</p>
                        <h3 class="subsection-heading">Aggressive</h3>
                        <p>Localized (stage I or II) aggressive NHL, deep X-ray therapy (DXT) with adjuvant combination chemotherapy (CCT) (e.g. three cycles of CHOP, a 21-day cycle of cyclophosphamide, hydroxy daunorubicin (Adriamycin), vincristine and prednisolone). Advanced stage aggressive NHL is treated with CCT (up to complete remission plus at least two cycles) followed by DXT to sites of bulky disease. Patients with lymphoblastic lymphoma are best treated with the very aggressive CCT regimes used for acute lymphoblastic leukaemia; such patients are candidates for allogeneic stem cell transplantation (see Chapter 38).</p>
                        <h3 class="subsection-heading">Indolent</h3>
                        <p>Asymptomatic patients may be followed closely without therapy for months or even years. When treatment is required, options include DXT, single agent chemotherapy (e.g. oral chlorambucil) and CCT with or without DXT. The relapse rate is high. Trials of aggressive chemotherapy followed by stem cell transplantation are in progress for younger patients.</p>
                    </div>
                </section>

                <section id="relapsed-disease" class="content-section" aria-labelledby="section-heading-8">
                    <h2 id="section-heading-8" class="section-heading">
                        <span class="heading-text">Relapsed disease</span>
                    </h2>
                    <div class="content-card">
                        <p>Over 50% of NHL patients will relapse after initial therapy. Indolent NHL will typically respond to single agent, CCT or radiotherapy. Relapsed aggressive NHL carries a poor prognosis but may respond to second-line CCT regimes followed by autologous or allogeneic stem cell transplantation.</p>
                    </div>
                </section>

                <section id="new-therapies" class="content-section" aria-labelledby="section-heading-9">
                    <h2 id="section-heading-9" class="section-heading">
                        <span class="heading-text">New therapies</span>
                    </h2>
                    <div class="content-card">
                        <p>The use of monoclonal antibodies, interleukin-2, interferon, new chemotherapeutic agents (e.g. fludarabine, 2-chlorodeoxy-adenosine (2-CDA) in indolent lymphomas) and the use of antisense oligonucleotides to the oncogene BCL-2 are under current investigation.</p>
                    </div>
                </section>

                <section id="prognosis" class="content-section" aria-labelledby="section-heading-10">
                    <h2 id="section-heading-10" class="section-heading">
                        <span class="heading-text">Prognosis</span>
                    </h2>
                    <div class="content-card">
                        <p>Prognosis in NHL is largely dependent on histology. The presence of bulky disease, multiple sites of extranodal involvement, age, performance status and laboratory parameters, such as LDH level and $\beta$2 microglobulin level, all influence prognosis. Long-term side effects of therapy are considered in Chapter 39.</p>
                    </div>
                </section>
                
                <section id="real-classification" class="content-section" aria-labelledby="section-heading-11">
                    <h2 id="section-heading-11" class="section-heading">
                        <span class="heading-text">The REAL classification</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">B-cell neoplasms</h3>
                        <h4>Indolent/chronic (untreated survival measured in years)</h4>
                        <h5>Indolent disseminated lymphoma/leukaemia</h5>
                        <ul>
                            <li>B-cell CLL/PLL/SLL</li>
                            <li>Lymphoplasmacytic lymphoma</li>
                            <li>Hairy cell leukaemia</li>
                            <li>Plasmacytoma/myeloma</li>
                            <li>Splenic marginal zone lymphoma/SLVL</li>
                        </ul>
                        <h5>Indolent extranodal lymphomas</h5>
                        <ul>
                            <li>Extranodal marginal zone/MALT Lymphoma</li>
                        </ul>
                        <h5>Indolent nodal lymphomas</h5>
                        <ul>
                            <li>Follicle centre lymphoma (follicular lymphoma) (grades 1, 2, 3)</li>
                            <li>Mantle cell lymphoma</li>
                        </ul>
                        <h4>Aggressive (untreated survival measured in months)</h4>
                        <ul>
                            <li>Diffuse large B-cell lymphoma</li>
                        </ul>
                        <h4>Highly aggressive (untreated survival measured in weeks)</h4>
                        <ul>
                            <li>Precursor B-lymphoma leukaemia/lymphoma</li>
                            <li>Burkitt's lymphoma</li>
                        </ul>
                        <h3 class="subsection-heading">T-cell and NK-cell neoplasms</h3>
                        <h4>Indolent/chronic</h4>
                        <ul>
                            <li>T-cell CLL/PLL</li>
                            <li>Large granular lymphocyte leukaemia (LGL)</li>
                            <li>Mycosis fungoides</li>
                        </ul>
                        <h4>Aggressive</h4>
                        <ul>
                            <li>Anaplastic large-cell lymphoma</li>
                            <li>Peripheral T-cell lymphomas (subtypes)</li>
                        </ul>
                        <h4>Highly aggressive</h4>
                        <ul>
                            <li>Precursor T-lymphoblastic leukaemia/lymphoma</li>
                            <li>Adult T-cell lymphoma/leukaemia (HTLV-1)</li>
                        </ul>
                        <h3 class="subsection-heading">Hodgkin lymphoma</h3>
                        <ul>
                            <li>Lymphocyte predominance, nodular ± diffuse</li>
                            <li>Classic HD
                                <ul>
                                    <li>Nodular sclerosis</li>
                                    <li>Mixed cellularity</li>
                                    <li>Lymphocyte depletion</li>
                                    <li>Lymphocyte-rich classical HD</li>
                                </ul>
                            </li>
                            <li>Diffuse large cell lymphoma, Hodgkin's-like/related</li>
                        </ul>
                        <p><em>* Small lymphocytic lymphoma</em></p>
                        <p>The REAL (Revised European American Lymphoma) classification. CLL, chronic lymphocytic leukaemia; HD, Hodgkin's disease; PLL, prolymphocytic leukaemia; SLL, small lymphocytic lymphoma SLVL, splenic lymphoma with villous lymphocytes.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-25-lymphoma-I-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 65%;"></div>
                        </div>
                       <span class="progress-text">Lecture 26 of 40</span>
                    </div>
                    <a href="haematology-27-myeloproliferative-disorders.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>